Loading…

Medical Research Finder

meRfi® Microbiome - The Digital Gut Microbiome Reference (incl. AI Chat)
Prebiotics, Probiotics, FMT / Manipulators of the Intestinal Microbiota

AuthorsReferences (Sources)

Zanubrutinib & Chronic lymphocytic leukemia (CLL) / Small lymphocytic lymphoma (SLL)

Welcome to meRfi Microbiome!

Please register to continue your trial period!

meRfi Microbiome provides you with up-to-date, evidence-based insights on the gut microbiota and related health topics.

Access our ever-expanding digital library and get personalized answers through our interactive AI chat platform.

Start your free trial and transform your understanding of the gut microbiota today!

Zanubrutinib is approved by the FDA and by the EMA for adult patients with Chronic lymphocytic leukemia (CLL) / Small lymphocytic lymphoma (SLL) supported by: Phase III SEQUOIA trial (treatment-naive CLL/SLL) and phase III ALPINE trial (relapsed or refractory CLL/SLL). The EMA label explicitly covers CLL (1, 2)

(1) Tam et al. 2022 Lancet Oncology 23: 1031-1043
(2) Hillmen et al. 2023a J Clin Oncol 41:1035-1045

see also:
[Bruton's tyrosine kinase (BTK) inhibitors & Chronic lymphocytic leukemia (CLL) / Sma…

Zanubrutinib versus bendamustine and rituximab in untreated chronic lymphocytic leukaemia and small lymphocytic lymphoma (SEQUOIA): a randomised, controlled, phase 3 trial
Tam et al. 2022 Lancet Oncology 23: 1031-1043
Zanubrutinib Versus Ibrutinib in Relapsed/Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma: Interim Analysis of a Randomized Phase III Trial
Hillmen et al. 2023a J Clin Oncol 41:1035-1045

7/1/2026